EOS authorized to sell product in Japan

PARIS – EOS imaging (Paris: EOSI, NYSE Euronext, FR0011191766-EOSI), the pioneer in orthopaedic 2D/3D imaging, said Japanese regulatory authorities have authorized the sale of EOS? and sterEOS?, which offer very low radiation dose 2D and 3D X-ray imaging of the full body in a natural weight-bearing position (standing or sitting). It has already been approved for sale in more than 30 countries.

EOS made its first forays into the Japanese market this year with the signing of a distribution agreement. Japan accounts for 17% of the global medical imaging market, making it the world’s second-largest market after the United States.

 “We are delighted to have obtained authorization to deploy our technology in Japan, which marks a key step in our commercial development in the Asia-Pacific region. In the run-up to obtaining this authorization, we worked for a number of months alongside our local distributor to raise awareness about the benefits of EOS among opinion leaders, who have expressed a great deal of interest in our technology. This positive feedback from the Japanese market supports our development strategy in this country,” CEO Marie Meynadier said.

EOS imaging designs, develops, and markets revolutionary and patented medical imaging systems based on technology that enabled George Charpak to win the Nobel Prize for Physics. The company is authorized to market the system in 31 countries, including the United States, Japan, Canada and Australia.